Key Takeaways
- MAIA Biotechnology receives a European patent for ateganosine-based analogues aimed at disrupting telomeres in cancer cells.
- Ateganosine enhances immune responses and shows promise in treating non-small cell lung cancer (NSCLC).
- MAIA’s intellectual property portfolio includes 10 issued patents and 24 pending applications worldwide.
Patent Approval and Implications
MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical firm, recently announced the European Patent Office’s decision to grant a patent for a range of ateganosine-based analogues. This patent covers innovative approaches for telomere-targeting anticancer therapy using ateganosine (THIO), either alone or in combination with checkpoint inhibitors (CPIs). The patent, invented by MAIA’s Chief Scientific Officer Dr. Sergei M. Gryaznov and Scientific Advisory Board member Dr. Jerry W. Shay, emphasizes the significance of these cancer-fighting immunosuppressive agents.
Dr. Gryaznov highlighted that mercaptopurine nucleoside analogues disrupt telomere structure and dampen immune system activity, leading to cancer cell death. He stated that these novel compounds promise enhanced specificity for cancer cells, representing a crucial advancement in MAIA’s cancer treatment platform. MAIA’s Chairman and CEO, Dr. Vlad Vitoc, also indicated that this intellectual property will strengthen the global standing of their first-in-class telomere-targeting compounds.
Details About Ateganosine
Ateganosine (THIO) is a pioneering investigational agent in clinical trials, targeting telomeres and aiming to improve outcomes for patients with non-small cell lung cancer (NSCLC). Telomeres and the enzyme telomerase are essential for cancer cell survival and their resistance to existing treatments. The modified nucleotide 6-thio-2’-deoxyguanosine effectively alters telomerase activity, induces DNA damage, and promotes the selective death of cancer cells.
In preclinical studies, combining ateganosine with PD-(L)1 inhibitors showcased significant, lasting tumor regression, thanks to the induction of immune memory specific to cancer types. Currently, ateganosine is being evaluated as a second-line treatment for NSCLC patients who have not responded to standard care involving checkpoint inhibitors.
About MAIA Biotechnology
MAIA Biotechnology is dedicated to developing targeted therapies and novel immuno-oncology drugs intended to significantly improve survival rates for cancer patients. Their lead program focuses on ateganosine, a telomere-targeting agent aimed at treating NSCLC characterized by telomerase-positive cancer cells. For more information, visit www.maiabiotech.com.
The content above is a summary. For more details, see the source article.